Sign up now and fund within 24h to get A$10.
Claim It Now

CSL Limited

1 day chart

Get A$10 trading credit to start you off

Sign up and fund a new Stake AUS account and enjoy an extra A$10 trading credit on us.

Sign up and fund a new Stake AUS account and get A$10 bonus trading credit.

T&Cs apply
Claim now
Get A$10 trading credit to start you off

About CSL

CSL Limited (CSL) is a global biotechnology company engaged in research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines. CSL's operating model is based around four key value creation activities: early stage research, product translation, manufacturing, and patient access. CSL's commercial and functional areas operate globally.

Buy Australian shares starting with CSL. Invest today with a CHESS-sponsored investing platform!

Sector

Health Care

CEO

-

Industry

Biotechnology

Website

csl.com.au

Market Capitalisation

$139.9B

Price-earnings ratio

35.12

Dividend yield

1.39%

High today

$290.00

Low today

$287.43

Open price

$289.90

52-week high

$313.55

52-week low

$228.65


Announcements





What does CSL Limited (CSL) do and how does it make money?

We're talking about the fifth largest biotech company in the world right now. Headquartered in Melbourne, CSL Limited (CSL) is a researcher, developer, manufacturer, marketer, and distributor of biopharmaceutical and allied products. When it comes to protein therapies and influenza vaccines, it is the world's first and second largest company.

This global biotech leader predominantly operates in Australia, the USA, Germany, the United Kingdom, Switzerland and China, and also has a strong presence in the Netherlands, Japan and Hong Kong.

CSL records revenue via two distinct businesses: CSL Behring and Seqirus. 

CSL Behring

CSL Behring’s medicines help to treat people with rare and/or serious immunological, haematological, respiratory, cardiovascular and metabolic diseases. It also conducts early stage research on plasma and non-plasma therapies, excluding influenza.

CSL Behring has markets in more than 100 countries across the Asia Pacific, Europe, Latin America and North America. It commercialises intellectual property to receive licence and royalty income and undertakes the bulk of administrative and corporate functions to support CSL as a whole.

CSL Behring’s revenue makes up more than 80% of CSL’s overall revenue.

Seqirus

Seqirus researches, develops, manufactures and distributes non-plasma biotherapeutic products. It's a leading influenza vaccine provider and a major contributor to the prevention of influenza, globally. It is also a transcontinental partner in pandemic preparedness. 

Utilising both egg-based and cell-based manufacturing technologies, Seqiris offers a broad range of seasonal, pre-pandemic and pandemic influenza vaccines to people all over the world.

With commercial operations in more than 20 countries, Seqirus aims to “lessen the severity and impact of influenza, which can reach epidemic or even pandemic proportions with life-threatening consequences”.

Seqirus is also the world’s only supplier of a unique range of products made for the Australian Government, including antivenoms and Q fever vaccine.

What does CSL stand for?

CSL stands for Commonwealth Serum Laboratories. 

CSL was founded in 1916 with the purpose of providing Australians with quick access to 20th century medical advances such as insulin, penicillin, vaccines against influenza, polio and other infectious diseases.

Is CSL a profitable company?

Yes, CSL is a profitable company.

Between FY2012 and FY2021, the company’s revenue grew at a steady compound annual growth rate (CAGR) of 9.5% from A$6.41b to A$14.51b.

The company’s net income also grew at a steady CAGR of 10.01% from A$1.42b to A$3.36b for the same period.

At the end of FY2021, CSL held A$2.76b of free cash flow on its books.

Is CSL a good buy?

CSL has grown its numbers along its top and bottom lines for an entire decade without fail. The company is also a consistent dividend payer. For long-term investors, CSL may be a good stock to buy and hold. 

Other investors may be wary of inflationary pressures, escalating interest rates and the knock-on effects of geopolitical tensions between Russia and Ukraine, and even China and Australia at this time.

Does CSL stock pay dividends?

Yes, CSL has distributed dividends to shareholders twice a year since 2010.

In 2021, CSL paid a dividend of $1.35 in April and another dividend of A$1.59 in September. The total for the year came to $2.94 per share.

In 2022, CSL paid its first dividend of A$1.42 in April. The company paid the final dividend on 5 October 2022, of $1.86.

The company does not offer a dividend reinvestment plan to owners of the stock.

Who owns CSL stock?

The general public holds 73.1% of all CSL stock. Institutions hold 26.8% and individual insiders own 0.1%.

Some institutions with the largest ownership include BlackRock (5.68%), The Vanguard Group (4.26%), BNP Paribas Arbitrage Sa, Asset Management Arm (1.7%), Norges Bank Investment Management (1.43%), WCM Investment Management, LLC (1%), Colonial First State Investments Limited (0.92%), Capital Research and Management Company (0.83%), Commonwealth Superannuation Corporation (0.64%) and Geode Capital Management, LLC (0.53%).

How do I buy CSL stock?

Stake offers a quick and easy way to purchase CSL shares – along with 2,000+ other Australian stocks and ASX ETFs – for a brokerage fee of only A$3.

Stake is CHESS sponsored, meaning that when you invest in ASX stocks, you get a HIN (Holder Identification Number) and stocks are held in your name.

With Stake, you can be in the market in under 5 minutes, whether it's the ASX or Wall St. If you’re interested in building your portfolio by adding CSL, sign up today.

Ready to start your investing journey with Stake?

Open an account

CSL FAQs

  1. Find the right investing platform for you. To buy CSL shares in Australia, you’ll need to open an account with an investing platform that offers the security. Try Stake, you can sign up in minutes.
  2. Fund your brokerage account. Once you are set up you can deposit into your account with different payment methods.
  3. Search for CSL or CSL Limited. Find the stock by using the search function and go to the CSL page.
  4. Place an order to buy CSL. Press the ‘Buy’ button and choose an order type to place your trade. Depending on the order type, the trade will go through straight away or when a price target is hit.
  5. Monitor your portfolio. You’ve now purchased some CSL shares. Stay on top of your portfolio and monitor its performance. You may be eligible for dividends and shareholder voting rights that affect your stock.

The ticker symbol for CSL Limited is CSL.

One share of CSL is valued at $288.72 as of 07 October 2024.

As of 07 October 2024 CSL Limited has a market cap of $139.9B.

Yes, CSL does pay dividends.

The dividend yield for CSL is 1.39% as of 07 October 2024.

The most recent CSL dividend distribution paid $2.17 per share on 02 October 2024.

The ex-dividend date of CSL was 09 September 2024.

The Price to Earnings ratio of CSL is 35.12.

The Earnings Per Share of CSL is $8.23.

The CSL Limited 52-week high stock price is $313.55.

The CSL Limited 52-week low stock price is $228.65.

Yes, the Stake investing platform allows you to buy CSL shares and over 12,000 more stocks and ETFs across the ASX and Wall St.

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in CSL
on Stake

Buy CSL from AU$3 brokerage

Invest in 2,500+ Aussie stocks and ETFs

CHESS-sponsored ASX trades

Get started
Canstar award phone
CSL related stocks

Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610105505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2024 Stake. All rights reserved.